Form4insider filings, from the source

SEC Form 4 · accession 0001144204-15-013928

Jazz Pharmaceuticals plc · JAZZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Mar 2, 2015
Accepted (ET)
Mar 4, 2015 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Ordinary SharesF1,F9Mar 2, 2015S588$172.5983D332,733IBy Longitude Venture Partners, L.P.
Ordinary SharesF2,F9Mar 2, 2015S1,862$175.0638D330,871IBy Longitude Venture Partners, L.P.
Ordinary SharesF3,F9Mar 2, 2015S2,854$176.0244D328,017IBy Longitude Venture Partners, L.P.
Ordinary SharesF4,F9Mar 2, 2015S4,302$176.7923D323,715IBy Longitude Venture Partners, L.P.
Ordinary SharesF9Mar 2, 2015S197$177.51D323,518IBy Longitude Venture Partners, L.P.
Ordinary SharesF5,F9Mar 2, 2015S12$172.5983D6,667IBy Longitude Capital Associates, L.P.
Ordinary SharesF6,F9Mar 2, 2015S38$175.0638D6,629IBy Longitude Capital Associates, L.P.
Ordinary SharesF7,F9Mar 2, 2015S57$176.0253D6,572IBy Longitude Capital Associates, L.P.
Ordinary SharesF8,F9Mar 2, 2015S87$176.7928D6,485IBy Longitude Capital Associates, L.P.
Ordinary SharesF9Mar 2, 2015S3$177.51D6,482IBy Longitude Capital Associates, L.P.
Ordinary Sharesholding———1,650D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.